Icelandic biosimilar developer Alvotech has signed a long-term manufacturing agreement with LOTTE Biologics for US-based production. A day earlier, the FDA approved a second production suite in Reykjavik for its Humira biosimilar SIMLANDI.

Beactica Therapeutics has selected BEA-28 as a preclinical candidate in its TEAD program, which aims to develop new therapies for aggressive, hard-to-treat solid tumors, including cancers that have become resistant to existing treatments.

AstraZeneca has opened its newest global strategic R&D center in Kendall Square, Cambridge, Massachusetts. It is part of a USD 1 billion investment that will grow the company’s workforce in the state by more than 50%.

Bergen-based Lifecare has manufactured its first functional continuous glucose monitoring (CGM) implants through its own operations, rather than through an external contract manufacturer. The company calls it an important step toward controlled manufacturing of its implantable sensor technology.

FluoGuide has entered a collaboration with medical technology company Leica Microsystems to advance precision surgery for brain tumors by combining its lead product, FG001, with Leica’s surgical microscope systems.

Umeå-based biotech Omnio has raised EUR 2.9 million in an oversubscribed round from existing investors and shareholders. The funding will move the company’s plasminogen-based therapy for hard-to-heal chronic wounds closer to clinical trials, with patient studies planned for 2027.

Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.

Hansa Biopharma has signed a collaboration with Amsterdam-based Cradle. Hansa will use Cradle’s AI-driven protein design and engineering platform across its research and development work to develop new immunomodulatory treatments for severe autoimmune diseases.

Stockholm-Uppsala has built substantial clinical, research, and manufacturing capabilities around advanced therapies. Bringing those strengths closer to the region’s expertise in proteomics, genomics, and other molecular technologies could help answer the next questions in cell and gene therapy: why treatments work, why they fail, and how more patients can benefit.

Henri B. Kagan and Kenso Soai are awarded the Nobel Prize in Chemistry 2026 for discovering how chemical reactions can produce only one of two mirror-image molecules. Their work shows how this kind of asymmetry can arise, and has been decisive for chemists designing reactions to make pharmaceuticals.

The Nobel Assembly at Karolinska Institutet has decided to award the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics.

Disrupted regulation of the hormone aldosterone is one of the main causes of resistant hypertension, according to a large genetic study led by Amgen deCODE genetics. The findings suggest more patients could benefit from drugs that block aldosterone.